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Introduction
Introduction
People with type 1 diabetes must rely on exogenous insulin to
regulate blood glucose
Ideally, try to keep blood glucose (BG) in the range 4-8 mmol/L
A too low glucose concentration (hypoglycemia) has immediate effects:
seizures, coma, brain damage or even death
A too high glucose concentration (hyperglycemia) has long-term
effects: blindness, nerve disease, kidney disease etc.
Introduction
Introduction
Continuous Subcutaneous Injection of Insulin (CSII)
Continuous Glucose Monitor (CGM) to measure subcutaneous glucose
Insulin pump injects insulin subcutaneously
The patient decides on the insulin dosage: preset continuous insulin
injections (basal rate) + bigger discrete insulin injections before
mealtimes, or if the BG is too high (boluses)
Main issues:
Sensor accuracy, even if correctly calibrated
Insulin action time
Daily variations in physiology
Human factor
Introduction
The artificial pancreas
Closed-loop control of blood glucose (here, using MPC) using a CGM
and an insulin pump
Continuous Glucose 
Monitor (CGM)
Insulin Pump
Control Algorithm
Artificial Pancreas
Test our closed-loop controller for two ”pilot” studies on the same
patient at Hvidovre Hospital
Material and methods
The clinical protocol
Overnight =⇒ No meal
2 Randomized cross-studies
Open - Loop
Closed - Loop
Open - Loop
Closed - Loop
6 patients
3
3
1 night 1 night1-4 weeks
Compare overnight CSII therapy vs. closed-loop control ability to
Stabilize blood glucose
Bring blood glucose to target
Scenario:
The patient arrives at 16:00.
A meal is consumed at 18:00 and an insulin bolus is administrated.
The loop is closed at 22:00 (for closed-loop studies only).
The closed-loop ends at 07:00 the following day (for closed-loop
studies only).
Material and methods
The Graphical User Interface
Glucose measurement from CGM provided to the software every 5
minutes (if available)
Discrete insulin injection every 15 minutes implemented by hand
Controller design
Patient model computation
No use of prior data
Instead, use of empirically estimated patient parameters
Basal insulin (in U/hr): Insulin needed to keep BG constant
Insulin sensitivity factor (ISF) (in mmol/L/U): Decrease in BG per unit of insulin
Insulin action time (in hours): Time to reach the minimum BG
Second order transfer function model from insulin to glucose
Y (s) = G(s)U(s), G(s) =
K
(τs + 1)2
Example: Impulse response for a simulated patient (Bolus size: 0.1U)
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Hovorka model
Second order approximation
Basal insulin: 0.4 U/hr
ISF: 4 mmol/L/U
Insulin action time: 4 hours
Controller design
ARMAX model
Y (s) = G(s)U(s), G(s) =
K
(τs + 1)2
Discretization of the previous transfer function model
A¯(q−1)y(t) = q−nk B¯(q−1)u(t)+ξ(t)
where
A¯(q−1) = 1 + a¯1q−1 + a¯2q−2
B¯(q−1) = b¯1q−1 + b¯2q−2
Offset-free description
A(q−1)y(t) = B(q−1)u(t) + (1− αq−1)e(t)
in which
A(q−1) = (1− q−1)A¯(q−1)
B(q−1) = (1− q−1)B¯(q−1)
0 ≤ α ≤ 1
may be realized as a stationary state space model in innovation form
xk+1 = Axk + Buk + Kεk
yk = Cxk
Controller design
MPC with soft output constraints
min
{uk+j ,vj}N−1j=0
φ =
1
2
N−1∑
j=0
‖yˆk+j+1|k − rˆk+j+1|k‖22 + λ‖∆uk+j‖22 + κ‖vk+j‖22
s.t. xˆk+1|k = Axˆk|k−1 + Buk + Kεk
yˆk+1|k = Cxˆk+1|k
xˆk+j+1|k = Axˆk+j|k + Buk
yˆk+j+1|k = Cxˆk+j+1|k
umin ≤ uk+j ≤ umax
Gmin − yˆk+j+1|k ≤ vk+j
vj ≥ 0
yˆk+j+1|k j+1 step ahead predictions of glucose
rˆk+j+1|k glucose setpoint
uk+j predicted insulin injections
Penalize low BG, ie. yˆk+j+1|k ≤ Gmin
Controller design
Glucose reference signal
Reduce the risk of low BG
Improve the stability of the controller
The time constant determines the aggressiveness of the controller
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Normoglycemic range
τ = 60 min
τ = 120 min
τ = 180 min
τ = 240 min
τ = 300 min
Controller design
Results
Use the right CGM for control
Insulin overdose followed by severe hypoglycemia
18:00 20:00 22:00 00:00 02:00 04:00 06:002
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Normoglycemic range
Reference
Left CGM
Right CGM
Average
YSI
Hemocue
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Insulin (suggested)
Insulin (injected)
Controller design
Example of prediction
Only based on the 2 last observations
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Normoglycemic range
Reference
Blood glucose (measured)
Blood glucose (predicted)
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Injected insulin
Predicted insulin
Controller design
Observer design
We consider an ARMAX model
A(q−1)y(t) = B(q−1)u(t) + C(t)e(t)
where
A(q−1) = 1 + a1q
−1 + a2q
−2 + a3q
−3 = (1 − q−1)A¯(q−1)
B(q−1) = b1q
−1 + b2q
−2 + b3q
−3 = (1 − q−1)B¯(q−1)
C(q−1) = 1 + c1q
−1 + c2q
−2 + c3q
−3 = (1 − αq−1)(1 − β1q−1)(1 − β2q−1)
and its reformulation in the innovation form
xk+1 = Axk + Buk + Kεk
yk = Cxk
Goal: Choose α, β1 and β2 which are the roots of the characteristic polynomial of
A− KC
χ(z) = z3 + c1z
2 + c2z + c3
based on data from the previous study (ie. estimate process and output noise variances),
such that the reconstruction error vanished less rapidly. Here:
β1,2 = 0.8 ± 0.15i
Controller design
Example of prediction with the redesigned observer
More taking the global trend of BG into account
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Normoglycemic range
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Blood glucose (measured)
Blood glucose (predicted)
0 2 4 6 8 10 12 140
2
4
Time [hr]
In
su
lin
 [U
/hr
]
 
 
Injected insulin
Predicted insulin
Controller design
Results - 2nd study
Use the left CGM for control
Still some insulin overdose
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Normoglycemic range
Reference
Left CGM
Right CGM
Average
YSI
Hemocue
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Conclusion
Conclusion and discussion
Overnight closed-loop control of BG
Importance of observer design for control
Still few issues related to insulin overdosing
Need to handle more carefully parameter variability for further trials
Do not inject insulin if the BG is too low
Overestimate the gain
Underestimate the time constant
